Abstract
Folic acid (FA) has high affinity to folate receptors (FRs), which have three isoforms: FRα, FRβ and FRγ. Among them, FRα is a tumor specific receptor, as it is frequently over-expressed in diverse malignancies but not in normal tissues. In this study, we have conjugated FA to a chitosan-poly(ethylenimine) copolymer, and have confirmed the low cytotoxicity of the product (namely “CP1.3K-FA”) in cancer cells. The transfection efficiency of CP1.3K-FA has been shown by the EGFP transfection assay to be higher than that of the unmodified chitosan-poly(ethylenimine) copolymer under optimal conditions. Results of the luciferase activity assay have also indicated that the transfection efficiency of CP1.3K-FA is comparable to that of Fugene HD in B16 and U87 cells. Our results have suggested that CP1.3K-FA warrants further development as a vector for gene delivery in cancer cells.
Keywords: Chitosan, Folic acid, Gene transfer, Non-viral vectors, Poly(ethylenimine), Targeting.
Current Gene Therapy
Title:Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells
Volume: 15 Issue: 5
Author(s): Wing-Fu Lai and Marie C. Lin
Affiliation:
Keywords: Chitosan, Folic acid, Gene transfer, Non-viral vectors, Poly(ethylenimine), Targeting.
Abstract: Folic acid (FA) has high affinity to folate receptors (FRs), which have three isoforms: FRα, FRβ and FRγ. Among them, FRα is a tumor specific receptor, as it is frequently over-expressed in diverse malignancies but not in normal tissues. In this study, we have conjugated FA to a chitosan-poly(ethylenimine) copolymer, and have confirmed the low cytotoxicity of the product (namely “CP1.3K-FA”) in cancer cells. The transfection efficiency of CP1.3K-FA has been shown by the EGFP transfection assay to be higher than that of the unmodified chitosan-poly(ethylenimine) copolymer under optimal conditions. Results of the luciferase activity assay have also indicated that the transfection efficiency of CP1.3K-FA is comparable to that of Fugene HD in B16 and U87 cells. Our results have suggested that CP1.3K-FA warrants further development as a vector for gene delivery in cancer cells.
Export Options
About this article
Cite this article as:
Lai Wing-Fu and Lin C. Marie, Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120347
DOI https://dx.doi.org/10.2174/1566523215666150812120347 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency
Current Gene Therapy New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy New Drugs for Follicular Lymphoma in Older Adults
Anti-Cancer Agents in Medicinal Chemistry The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Differential Network Analysis in Human Cancer Research
Current Pharmaceutical Design “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery